Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL Treatment

By HEOR Staff Writer

February 17, 2026

Glofitamab Cost-Effectiveness in R/R DLBCL Reimbursement

Glofitamab cost-effectiveness analysis by Zorginstituut Nederland supports conditional inclusion of glofitamab (Columvi®) with gemcitabine and oxaliplatin (Glofit-GemOx) in the basic insurance package for adults with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) ineligible for autologous stem cell transplantation (auto-SCT). This February 12, 2026, reassessment—detailed in the Zorginstituut Nederland pakketadvies—overturns a prior negative advice based on phase III STARGLO data showing overall survival (OS) gains over rituximab-GemOx (R-GemOx), despite low evidence quality.

STARGLO Survival Gains vs. R-GemOx

STARGLO demonstrates median OS of 25.5 months (95% CI: 18.3-NR) for Glofit-GemOx versus 12.9 months (95% CI: 7.9-18.5) for R-GemOx (HR 0.62, 95% CI: 0.43-0.88), meeting PASKWIL criteria after adjustments. Therapeutic value tops chemo-immunotherapy (CIT), but list-price glofitamab cost-effectiveness yields ICER over €80,000/QALY (€94,584/QALY adjusted for Dutch age 73, generalized gamma PFS/log-logistic OS, 5-year progression-free costs, equal curative follow-ons).

Model Inputs Driving ICER

Partitioned survival analysis (45-year horizon, societal perspective) gives 3.92 QALYs for Glofit-GemOx versus 1.62 for R-GemOx (incremental 2.31 QALYs), with lifetime costs €318,147 versus €187,293 (incremental €130,855; €85,564 drug costs over 8.5 cycles). Base-case ICER (€94,584/QALY) incorporates Dutch age (+19%), conservative survival fits, 5-year monitoring (+13%), equal post-progression therapies (+15%), and age-aligned mortality. Probabilistic sensitivity (5,000 runs) shows 35% chance cost-effective at €80,000/QALY; EVPI €1,147/patient highlights data gaps.

Year-3 Budget and Safeguards

Year-3 uptake hits 131 patients (80-90% penetration in 2L+/non-curative lines from 1,616 annual DLBCL cases), with €12.0M gross spend (€91,978/patient) offset by €10.4M CIT savings, netting €10.7M. Safeguards include national registry for bispecific outcomes, use agreements, and 3-4 year evidence review on OS/age effects. Obinutuzumab covers CRS mitigation; failure risks exceed proportionality thresholds.

Pricing Mandates

Glofit-GemOx addresses unmet R/R DLBCL needs (10-15% refractory, 20-30% relapse post-R-CHOP; 6-12 month survival), advancing bispecifics amid CAR-T shifts. Glofitamab cost-effectiveness requires 28% discount to hit €80,000/QALY, enabling real-world HOVON data for iterative reviews versus evolving options like less-toxic CAR-T or monotherapy. Sluis mechanisms balance €12M oncology spend with fiscal sustainability.

Reference url

Recent Posts

Advancing Participatory Arts Health in Dutch Care Systems

By João L. Carapinha

March 30, 2026

Participatory arts health is gaining recognition as a valuable complement to traditional medical care, supporting both physical and psychosocial well-being for people living with chronic conditions and those at the end of life. In this article we explore how creative, participatory approaches ...
Advancing Tarlatamab for Small Cell Lung Cancer Treatment

By HEOR Staff Writer

New Treatment Option for Relapsed Extensive-Stage Small Cell Lung Cancer Tarlatamab small cell lung therapy has received a positive opinion from the European Medicines Agency (EMA) for marketing authorisation. The bispecific T-cell engager is recommended as monotherapy ...
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management

By HEOR Staff Writer

The US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) as the once-weekly basal insulin for adults with type 2 diabetes. This approval marks a major advancement in reducing treatment burden by decreasing basal insulin injections from seven to one per week.